gpl1 vs tirzepatide The GLP-1 Powerhouses: Semaglutide vs. Explained – Skippack Pharmacy Tirzepatide, a dual GIP/GLP-1 receptor

There is also a concern about the risk of pancreatitis and changes in thyroid function, necessitating monitoring and caution in patients with a history of thyroid disease

Studies consistently show that without pharmacological intervention, somewhere between 25% and 40% of weight lost during a diet comes from lean tissue

Conclusion Concerns about a potential pancreatic cancer signal with GLP-1 therapy originated from early reports and limited datasets

In another trial of liraglutide treatment for adolescents aged 1217 years, 88.8% of treated adolescents experienced adverse events, with 64.8% reporting nausea, vomiting, or diarrhea (compared to 36.5% of adolescents in the placebo group, where 84.9% experienced adverse events) (11, 35)